Important Announcement for Hong Kong Stocks.

1) Company News

$XINYI SOLAR (00968.HK)$The company's equity holders' share of comprehensive net income for the first half of 2024 is expected to increase by 35%-45% to HKD 1.3915 billion compared to the same period in 2023.

According to the announcement, the increase in net profit is mainly due to the relatively low profitability level of the group in the first half of 2023 compared to the first half of 2024; the sales volume of the group's main solar glass products in the first half of 2024 has increased compared to the same period of last year; and the group continuously improves production capacity and efficiency, as well as the decrease of several raw material and energy costs.

$GEELY AUTO (00175.HK)$First-quarter revenue was CNY 52.315 billion, up 56.14% year-on-year; net profit was CNY 1.561 billion, up 118.63% year-on-year.

According to the announcement, sales in the first quarter increased by 49% compared to the same period last year, with a total delivery of about 33,000 vehicles, up 117% from the same period last year. The gross margin was 12.3%, up 3.4 percentage points from 8.9% in the same period of 2023.

$LUK FOOK HOLD (00590.HK)$Annual revenue as of March 31 increased by 28% year-on-year to HKD 15.326 billion; net profit increased by 37.6% year-on-year to HKD 1.767 billion.

$TSE SUI LUEN (00417.HK)$Annual revenue as of March 31 increased by 2.5% year-on-year to HKD 2.655 billion; loss increased by 423.8% year-on-year to HKD 374 million due to a decrease in annual gross margin to 29.6% from 35.1% last year.

$LONGFOR GROUP (00960.HK)$Purchased back about USD 403 million of 3.95% senior notes and about USD 219.6 million of 3.85% notes.

$ZHEJIANGEXPRESS (00576.HK)$Zhejiang merchants capital, Zhejiang merchants investment, and Hefei Gaoxin Construction Investment Group plan to establish a fund with a maximum investment amount of CNY 500 million.

$HENLIUS (02696.HK)$The biosimilar HLX15 (recombinant anti-CD38 fully human monoclonal antibody injection) of Darzalex successfully completed phase 1 clinical studies.

2) Repurchase Dynamics

$TENCENT (00700.HK)$Purchased back 2.68 million shares for HKD 1.001 billion at a buyback price of HKD 371-375.6 per share.

$XIAOMI-W (01810.HK)$Purchased back 9 million shares for about HKD 149 million at a buyback price of HKD 16.44-16.62 per share.

$AIA (01299.HK)$Purchased back 1.33 million shares for about HKD 70.7045 million at a buyback price of HKD 52.85-53.6 per share.

$KUAISHOU-W (01024.HK)$Purchased back 638,000 shares for about HKD 29.5568 million at a buyback price of HKD 46.05-46.65 per share.

$CITIC (00267.HK)$The amount of shareholding by controlling shareholders, directors, and senior management has exceeded HKD 60 million.

Editor/ping